KYNB vs KYTX

Kyntra Bio, Inc. vs Kyverna Therapeutics, Inc. — Valuation Comparison 2026

By CirclFi Research Team · Updated 2026-06-03 · Data from SEC EDGAR, FRED & GDELT

Quick Summary — KYNB scores higher on quality with 5.3/10 vs KYTX's 4.2/10. KYNB trades at $6.84 while KYTX trades at $7.90. Both analyzed daily using SEC EDGAR data across 13 institutional models.

KYNB

Biotechnology
Kyntra Bio, Inc.
Quality
5.3
out of 10
Value Trap
47
WARN
Price
$6.84
Last close
Models
7/13
Active
VS

KYTX

Biotechnology
Kyverna Therapeutics, Inc.
Quality
4.2
out of 10
Value Trap
18
SAFE
Price
$7.90
Last close
Models
7/13
Active
KYNB
Dynamic NAV sees +138.7% upside
Value Trap 47/100 — caution
KYTX
2 models active
Quality 4.2/10 — below average

KYNB vs KYTX — Fair Value Comparison

KYNB
$0$6$13$19 Price$6.84 Bayesian …$16.17 (+132.7%) Dynamic N…$16.33 (+138.7%)
KYTX
$0$3$6$9 Price$7.90 Bayesian …$2.16 (-72.7%) Dynamic N…$3.58 (-54.6%)
Market Price Model 1 Model 2

Model-by-Model Comparison

ModelType KYNB Fair ValueKYNB Upside KYTX Fair ValueKYTX Upside
Bayesian DCF Intrinsic $16.17 +132.7% $2.16 -72.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $16.33 +138.7% $3.58 -54.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%

KYNB vs KYTX — Which Stock Is More Undervalued in 2026?

KYNB scores higher with a 5.3/10 quality rating vs KYTX's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do KYNB and KYTX Valuations Compare?

At $6.84, KYNB trades +132.7% below its Bayesian DCF fair value of $16.17, while KYTX at $7.90 trades +72.7% above its estimate of $2.16. KYNB shows a wider gap between price and intrinsic value.

Quality of Company: KYNB vs KYTX

KYNB earns a Quality of Company score of 5.3/10 compared to KYTX's 4.2/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: KYNB vs KYTX

KYNB carries a WARN value trap risk (47/100) while KYTX shows SAFE risk (18/100). Stocks with value trap scores above 40 may appear undervalued but face deteriorating fundamentals — declining margins, rising debt, or shrinking revenue can make the apparent discount a trap.

Both in Biotechnology

Both KYNB and KYTX operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare KYNB vs KYTX differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo  ·  FactSet: ~$1,000/mo  ·  CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

See all Biotechnology stocks →